Patents by Inventor Louis Licamele

Louis Licamele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prediction of QT prolongation based on SNP genotype
    Patent number: 8652776
    Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: February 18, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120058201
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120059035
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120035215
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 9, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • IDENTIFICATION OF A MOLECULAR SIGNATURE FOR ANTIPSYCHOTICS AND SERMS
    Publication number: 20110118313
    Abstract: Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS.
    Type: Application
    Filed: May 15, 2009
    Publication date: May 19, 2011
    Inventors: Christian Lavedan, Louis Licamele, Mihael H. Polymeropoulos
  • GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS
    Publication number: 20110021566
    Abstract: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
    Type: Application
    Filed: May 17, 2008
    Publication date: January 27, 2011
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE
    Publication number: 20100249188
    Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Application
    Filed: September 10, 2008
    Publication date: September 30, 2010
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20100226858
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: March 28, 2008
    Publication date: September 9, 2010
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton